Ondek
Darlinghurst
About Ondek
The company is developing an oral therapeutic candidate, ImmBALANCE®, derived from H. pylori, to treat paediatric allergy – which frequently manifests initially as atopic dermatitis (also known as eczema) and may progress to include food allergies, allergic asthma, allergic rhinitis and other allergic conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $2.8M
- Funding stage: Seed
- Last round: Seed (Jan 2006)
- Website: ondek.com
- Phone: +61 2 9332 0600
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/ondek-3359945 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.